Trial Profile

Phase 1 Trial: RD 799.35751 (ETH47-101)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ETH-47 (Primary) ; ETH-47 (Primary)
Indications Respiratory tract infections
Focus Adverse reactions; First in man
Acronyms ETH47-101
Sponsors ethris

Most Recent Events

30 Jan 2025 According to Ethris media release, Based on the encouraging Phase 1 results, Ethris filed a Clinical Trial Application (CTA) for a Phase 2a rhinovirus challenge study in asthma patients, planned to begin in Q2 2025.
30 Jan 2025 According to Ethris media release,company announced promising topline data from this trial at the mRNA-Based Therapeutics Summit Europe in Frankfurt, Germany.
18 Jun 2024 According to Ethris media release, full data readout is planned for the third quarter of 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com